Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Hybrigenics appoints Eric Castaldi to its Board of Directors


Paris, France, 7 October 2008 - Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced today the appointment of Eric Castaldi to its Board as a non-executive independent Director.

Eric Castaldi brings 20 years of financial experience, especially from the medical and biotechnology fields. He is CFO and a member of the Executive Committee of NicOx SA, an emerging pharmaceutical company listed on Eurolist in Paris, and which is specialized in the research and development of nitric oxide-donating drugs. Eric Castaldi joined NicOx in 1998 and was in charge of the company's IPO in November 1999 and subsequent financings for a total of EUR 312M, including a public follow-on, Private Investment in Public Equities (PIPE) offerings and a rights issue.

As a graduate in Finance, Accountancy and Administration from the University of Nice, Eric Castaldi started his career as Financial and Cost Accountant from 1986 to 1989 for Cordis Corporation, a US based company specialized in bio-surgical instrumentation. He joined in 1989 through 1997 My Kinda Town plc, a European leisure company, as CFO and COO, and served, after that, Safety Kleen Corporation, a U.S. based environmental waste company as CFO, where he was responsible for operations in France and Belgium.

Eric Castaldi's nomination will be put to the next Hybrigenics Shareholders Meeting for approval.

Daan Ellens, Chairman of the Board of Hybrigenics, declared: 'I am delighted to welcome Eric to our Board. His solid financing track record in the biotechnology sector and his in-depth experience of the challenges faced by listed companies will be very helpful to further structure our company'.

About Hybrigenics
Hybrigenics is a bio-pharmaceutical company focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-resistant prostate cancer in combination with Sanofi-Aventis' Taxotere(R), which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

Hybrigenics also offers a range of services to identify, validate and inhibit protein interactions to researchers in all areas of life sciences through its Hybrigenics Services unit, using its ISO 9001-certified high-throughput Yeast-Two Hybrid (Y2H) screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

NewCap.
Financial communication
Axelle Vuillermet / Pierre Laurent
Tel. : +33 (0)1 44 71 94 94
hybrigenics@newcap.fr

For further information, please contact:
Andrew Lloyd & Associates
Andrew Lloyd / Neil Hunter
Tel: +44 1273 675100
allo@ala.com / neil@ala.com


Publisher Contact Information:

NewCap.
+33 (0)1 44 71 94 94
hybrigenics@newcap.fr

Company profile of Hybrigenics
Past press releases of Hybrigenics.

Data


25,720
Tech investments
From our Online Data Service
16,652
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
May 17€4.0MBiopharmaceuticals
May 16€15.0MPayment software
May 16€4.0MInternet services
May 16€80.0MConsumer electronics
May 16€6.3MImaging
May 16€13.0MInternet services
May 16€34.5MBiotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises 1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.